Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.

Journal article

Fenaux P. et al, (2020), N Engl J Med, 382, 140 - 151

Oncogenic Drivers and Development

Journal article

Cruz Hernandez D. and Vyas P., (2019), Cancer Discovery, 9, 1653 - 1655

GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome.

Journal article

Garnett C. et al, (2019), IUBMB Life

Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)

Conference paper

DiNardo CD. et al, (2019), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 19, S217 - S218

DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation.

Journal article

Godfrey L. et al, (2019), Nat Commun, 10

Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.

Journal article

Marquis M. et al, (2019), Blood cancer journal, 9, 28 - 28

The Graft-Versus-Leukemia Effect in AML.

Journal article

Sweeney C. and Vyas P., (2019), Front Oncol, 9

The Inflammasome: More Than a Protective Innate Immune Mechanism

Journal article

Stoilova B. and Vyas P., (2019), Immunity

Load More